A study conducted by researchers at King’s College London suggests that compounds found in pomegranates may offer benefits for nearly 500,000 people in the United Kingdom living with a specific form of heart failure. The research focused on heart failure with preserved ejection fraction (HFpEF), a condition marked by the heart muscle becoming stiff and less able to relax between beats, which impairs its ability to fill with blood efficiently.
The key compound at the center of the study is urolithin A, a natural substance produced in the body after consuming certain foods, including pomegranates, walnuts, and some types of berries. According to the findings, urolithin A can relax the heart muscle, reduce scarring, and help prevent harmful enlargement of the organ. These effects may contribute to improving heart function in individuals affected by HFpEF.
Treatment options for HFpEF remain limited due to the complex nature of the condition, which is influenced by multiple factors such as aging, high blood pressure, and diabetes. Dr. Joseph Burgoyne, the senior author of the study, said the research demonstrates that urolithin A activates a pathway that enhances heart relaxation and lessens the severity of the disease. He indicated that this discovery opens the door to developing new therapies aimed at improving patient outcomes and quality of life.
Despite the promising results, Dr. Burgoyne cautioned that the current evidence does not support recommending pomegranate consumption as a direct treatment for heart failure. However, he noted that dietary approaches encouraging the production of urolithin A might offer a complementary strategy to help manage the condition.
Further research is needed to confirm these findings and explore the potential clinical applications of urolithin A in heart failure treatment. In the meantime, the study highlights the importance of dietary factors in cardiovascular health and provides a foundation for future investigations into natural compounds that could support heart function.